Skip to search formSkip to main contentSkip to account menu

drotrecogin alfa

Known as: Revombinant Human Autoprothrombin IIA, Activated, DROTRECOGIN ALFA (ACTIVATED), Drotrecogin alfa (activated), lyophilized 
A recombinant form of human protein C with anti-thrombotic, anti-inflammatory, and profibrinolytic properties.
National Institutes of Health

Related topics

Related topics

14 relations

Broader (2)

Anti-Infective AgentsProtein C
Brain NeoplasmsCerebral InfarctionCerebrovascular TraumaDrug Allergy

Narrower (1)

rhAPC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo…
Highly Cited
2009
Highly Cited
2009
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
Review
2007
Review
2007
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
Phillip H. Kuo, MD, PhD Emanuel Kanal, MD Ali K. Abu-Alfa, MD Shawn E. Cowper, MD Nephrogenic systemic fibrosis (NSF), described… 
Highly Cited
2005
Highly Cited
2005
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*
Objective:To provide further evidence for the efficacy and safety of drotrecogin alfa (activated) treatment in severe sepsis… 
Highly Cited
2003
Highly Cited
2003
Efficacy and safety of recombinant human activated protein C for severe sepsis
Objective: To find out whether activated recombinant protein C reduces the death rate from all causes at 28 days among patients… 
Highly Cited
1997
Highly Cited
1997
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.
Factor V Leiden (factor V Arg506Gln), the genetic defect underlying resistance to activated protein C, is the most common risk… 
Highly Cited
1995
Highly Cited
1995
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C
The aim of the study was to determine the respective influence of pretreatment serum hepatitis C virus (HCV) RNA levels and HCV… 
Highly Cited
1994
Highly Cited
1994
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
Heterozygous protein C deficiency is associated with an increased risk for thrombosis. This association is restricted to a… 
Highly Cited
1986
Highly Cited
1986
Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.
Human factor VIII was isolated from commercial factor VIII concentrates and found to consist of multiple polypeptides with… 
Highly Cited
1980
Highly Cited
1980
Regulation of activated protein C by a new protein. A possible function for bovine protein S.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)